Jun. 11 at 1:57 AM
$SCNX [Stochastics] Look at the 3YR Weekly Chart, and you will see just how much room the SP has yet to run from this level (IMO). It is still Oversold despite the progress that we have made over the last month. Two (2) FDA approved drugs targeting
$500MILS addressable market, additional promising drugs in the pipeline all targeting different markets, 2H-2025 commercialization on both FDA approved drugs, IP exclusivity to 2041, new CEO's with 60yr combined experience launching
$5-50Bils therapeutics through Forest Labs and ABBV. So much of the risk in small bio-pharma is FDA approval, and this Company has two (2) approved drugs set for commercialization and a
$15MILS valuation, 8Mils float. The ST board is growing - do you own research, read my posts - multiplier upside from this level (IMO) to
$6.0-6.5 at least on successful execution with lead products.
$DRUG $RGC
